NICE LTD - SPON ADR (NICE)

US6536561086 - ADR

176.02  +0.46 (+0.26%)

After market: 176.02 0 (0%)

Fundamental Rating

7

Taking everything into account, NICE scores 7 out of 10 in our fundamental rating. NICE was compared to 279 industry peers in the Software industry. While NICE belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. NICE has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings could make NICE a good candidate for value and growth investing.



8

1. Profitability

1.1 Basic Checks

NICE had positive earnings in the past year.
In the past year NICE had a positive cash flow from operations.
In the past 5 years NICE has always been profitable.
NICE had a positive operating cash flow in each of the past 5 years.

1.2 Ratios

NICE's Return On Assets of 8.15% is amongst the best of the industry. NICE outperforms 83.45% of its industry peers.
NICE has a better Return On Equity (11.85%) than 82.73% of its industry peers.
With an excellent Return On Invested Capital value of 10.60%, NICE belongs to the best of the industry, outperforming 86.69% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for NICE is significantly below the industry average of 12.23%.
The last Return On Invested Capital (10.60%) for NICE is above the 3 year average (7.04%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 8.15%
ROE 11.85%
ROIC 10.6%
ROA(3y)5.42%
ROA(5y)5.21%
ROE(3y)8.62%
ROE(5y)8.35%
ROIC(3y)7.04%
ROIC(5y)6.73%

1.3 Margins

NICE has a better Profit Margin (16.04%) than 82.73% of its industry peers.
In the last couple of years the Profit Margin of NICE has grown nicely.
NICE has a Operating Margin of 20.05%. This is amongst the best in the industry. NICE outperforms 88.13% of its industry peers.
NICE's Operating Margin has improved in the last couple of years.
NICE has a Gross Margin (66.70%) which is in line with its industry peers.
In the last couple of years the Gross Margin of NICE has remained more or less at the same level.
Industry RankSector Rank
OM 20.05%
PM (TTM) 16.04%
GM 66.7%
OM growth 3Y8.5%
OM growth 5Y6.54%
PM growth 3Y5.85%
PM growth 5Y5.11%
GM growth 3Y0.9%
GM growth 5Y0.63%

6

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), NICE is creating some value.
The number of shares outstanding for NICE has been reduced compared to 1 year ago.
The number of shares outstanding for NICE has been increased compared to 5 years ago.
NICE has a better debt/assets ratio than last year.

2.2 Solvency

NICE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.69
Altman-Z N/A
ROIC/WACC1.17
WACC9.03%

2.3 Liquidity

A Current Ratio of 1.66 indicates that NICE should not have too much problems paying its short term obligations.
With a Current ratio value of 1.66, NICE perfoms like the industry average, outperforming 51.08% of the companies in the same industry.
A Quick Ratio of 1.66 indicates that NICE should not have too much problems paying its short term obligations.
NICE has a Quick ratio of 1.66. This is comparable to the rest of the industry: NICE outperforms 52.16% of its industry peers.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.66

7

3. Growth

3.1 Past

NICE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.57%, which is quite impressive.
The Earnings Per Share has been growing by 13.44% on average over the past years. This is quite good.
Looking at the last year, NICE shows a quite strong growth in Revenue. The Revenue has grown by 13.52% in the last year.
Measured over the past years, NICE shows a quite strong growth in Revenue. The Revenue has been growing by 10.48% on average per year.
EPS 1Y (TTM)21.57%
EPS 3Y15.33%
EPS 5Y13.44%
EPS Q2Q%24.91%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y12.99%
Revenue growth 5Y10.48%
Sales Q2Q%14.74%

3.2 Future

Based on estimates for the next years, NICE will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.90% on average per year.
The Revenue is expected to grow by 12.15% on average over the next years. This is quite good.
EPS Next Y22.51%
EPS Next 2Y17.97%
EPS Next 3Y15.9%
EPS Next 5YN/A
Revenue Next Year14.99%
Revenue Next 2Y13.01%
Revenue Next 3Y12.15%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

8

4. Valuation

4.1 Price/Earnings Ratio

NICE is valuated correctly with a Price/Earnings ratio of 16.31.
NICE's Price/Earnings ratio is rather cheap when compared to the industry. NICE is cheaper than 86.33% of the companies in the same industry.
NICE's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.73.
The Price/Forward Earnings ratio is 13.74, which indicates a correct valuation of NICE.
Based on the Price/Forward Earnings ratio, NICE is valued cheaply inside the industry as 87.41% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of NICE to the average of the S&P500 Index (22.83), we can say NICE is valued slightly cheaper.
Industry RankSector Rank
PE 16.31
Fwd PE 13.74

4.2 Price Multiples

NICE's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. NICE is cheaper than 90.29% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of NICE indicates a rather cheap valuation: NICE is cheaper than 89.57% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 16.56
EV/EBITDA 12.54

4.3 Compensation for Growth

NICE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of NICE may justify a higher PE ratio.
NICE's earnings are expected to grow with 15.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.72
PEG (5Y)1.21
EPS Next 2Y17.97%
EPS Next 3Y15.9%

0

5. Dividend

5.1 Amount

NICE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

NICE LTD - SPON ADR

NASDAQ:NICE (12/20/2024, 8:26:59 PM)

After market: 176.02 0 (0%)

176.02

+0.46 (+0.26%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)11-14 2024-11-14/dmh
Earnings (Next)02-20 2025-02-20/amc
Inst Owners12.92%
Inst Owner Change-2.63%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap11.07B
Analysts83.75
Price Target254.29 (44.47%)
Short Float %3.41%
Short Ratio3.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.78%
Min EPS beat(2)0.4%
Max EPS beat(2)5.16%
EPS beat(4)4
Avg EPS beat(4)2.66%
Min EPS beat(4)0.4%
Max EPS beat(4)5.16%
EPS beat(8)8
Avg EPS beat(8)2.56%
EPS beat(12)11
Avg EPS beat(12)2.23%
EPS beat(16)15
Avg EPS beat(16)2.28%
Revenue beat(2)0
Avg Revenue beat(2)-1.52%
Min Revenue beat(2)-1.89%
Max Revenue beat(2)-1.15%
Revenue beat(4)0
Avg Revenue beat(4)-1.35%
Min Revenue beat(4)-1.89%
Max Revenue beat(4)-0.93%
Revenue beat(8)0
Avg Revenue beat(8)-1.34%
Revenue beat(12)2
Avg Revenue beat(12)-0.7%
Revenue beat(16)3
Avg Revenue beat(16)-0.49%
PT rev (1m)-8.76%
PT rev (3m)-3.94%
EPS NQ rev (1m)2.37%
EPS NQ rev (3m)3.33%
EPS NY rev (1m)-1.55%
EPS NY rev (3m)-0.52%
Revenue NQ rev (1m)-0.14%
Revenue NQ rev (3m)-0.14%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.11%
Valuation
Industry RankSector Rank
PE 16.31
Fwd PE 13.74
P/S 4.2
P/FCF 16.56
P/OCF 14.49
P/B 3.1
P/tB 7.54
EV/EBITDA 12.54
EPS(TTM)10.79
EY6.13%
EPS(NY)12.81
Fwd EY7.28%
FCF(TTM)10.63
FCFY6.04%
OCF(TTM)12.15
OCFY6.9%
SpS41.94
BVpS56.75
TBVpS23.36
PEG (NY)0.72
PEG (5Y)1.21
Profitability
Industry RankSector Rank
ROA 8.15%
ROE 11.85%
ROCE 14.05%
ROIC 10.6%
ROICexc 17.83%
ROICexgc 289.14%
OM 20.05%
PM (TTM) 16.04%
GM 66.7%
FCFM 25.34%
ROA(3y)5.42%
ROA(5y)5.21%
ROE(3y)8.62%
ROE(5y)8.35%
ROIC(3y)7.04%
ROIC(5y)6.73%
ROICexc(3y)11.62%
ROICexc(5y)10.72%
ROICexgc(3y)109.88%
ROICexgc(5y)N/A
ROCE(3y)9.33%
ROCE(5y)8.92%
ROICexcg growth 3YN/A
ROICexcg growth 5Y1.67%
ROICexc growth 3Y7.07%
ROICexc growth 5Y12.83%
OM growth 3Y8.5%
OM growth 5Y6.54%
PM growth 3Y5.85%
PM growth 5Y5.11%
GM growth 3Y0.9%
GM growth 5Y0.63%
F-Score7
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.69
Debt/EBITDA 0
Cap/Depr 48.28%
Cap/Sales 3.62%
Interest Coverage 250
Cash Conversion 105.16%
Profit Quality 158.01%
Current Ratio 1.66
Quick Ratio 1.66
Altman-Z N/A
F-Score7
WACC9.03%
ROIC/WACC1.17
Cap/Depr(3y)44.4%
Cap/Depr(5y)40.75%
Cap/Sales(3y)3.6%
Cap/Sales(5y)3.71%
Profit Quality(3y)163.21%
Profit Quality(5y)173.92%
High Growth Momentum
Growth
EPS 1Y (TTM)21.57%
EPS 3Y15.33%
EPS 5Y13.44%
EPS Q2Q%24.91%
EPS Next Y22.51%
EPS Next 2Y17.97%
EPS Next 3Y15.9%
EPS Next 5YN/A
Revenue 1Y (TTM)13.52%
Revenue growth 3Y12.99%
Revenue growth 5Y10.48%
Sales Q2Q%14.74%
Revenue Next Year14.99%
Revenue Next 2Y13.01%
Revenue Next 3Y12.15%
Revenue Next 5YN/A
EBIT growth 1Y31.88%
EBIT growth 3Y22.6%
EBIT growth 5Y17.7%
EBIT Next Year40.29%
EBIT Next 3Y15.63%
EBIT Next 5YN/A
FCF growth 1Y94.59%
FCF growth 3Y4.6%
FCF growth 5Y7.47%
OCF growth 1Y83.71%
OCF growth 3Y5.34%
OCF growth 5Y7.2%